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Aims To study initiation, dosages, and compliance with beta-blockers, angiotensin-converting enzyme
(ACE)-inhibitors, and statins in patients after acute myocardial infarction (AMI) and to identify likely
targets for improvement.
Methods and results Patients admitted with ﬁrst AMI between 1995 and 2002 were identiﬁed by linking
nationwide administrative registers. A total of 55 315 patients survived 30 days after discharge and were
included; 58.3% received beta-blockers, 29.1% ACE-inhibitors, and 33.5% statins. After 1, 3, and 5 years,
78, 64, and 58% of survivors who had started therapy were still receiving beta-blockers, 86, 78, and 74%
were receiving ACE-inhibitors, and 85, 80, and 82% were receiving statins, respectively. Increased age
and female sex were associated with improved compliance. The dosages prescribed were generally 50%
or less of the dosages used in clinical trials, and dosages did not increase during the observation period.
Patients who did not start treatment shortly after discharge had a low probability of starting treatment
later.
Conclusion The main problem with underuse of recommended treatment after AMI is that treatment is
not initiated at an appropriate dosage shortly after AMI. A focused effort in the immediate post-infarction
period would appear to provide long-term beneﬁt.
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Introduction
Beta-blockers, angiotensin-converting enzyme (ACE)-
inhibitors, and statins are recommended for most patients
following an acute myocardial infarction (AMI), but underuse
is widely documented.1,2 Underuse may involve not starting
therapy, poor compliance, and underdosing. Much attention
has focused on the fact that many patients are never
offered treatment,2 but compliance with treatment and
dosing has received less attention. Comprehensive analyses
of initiation, compliance, and dosing are necessary to learn
the likely targets for improving long-term use. Since 1995,
the Danish Registry of Medicinal Product Statistics has regis-
tered all prescriptions dispensed from pharmacies in
Denmark according to each patient’s unique civil registration
number. In this study, we linked data from this Registry with
data from the National Hospital Registry to study initiation of
treatment, drug dosages, and long-term compliance with
beta-blockers, ACE-inhibitors, and statins in 71 515 patients
after their ﬁrst AMI between 1995 and 2002.
Methods
The National Hospital Registry keeps records on all hospital admis-
sions in Denmark since 1978, and each hospitalization is classiﬁed
according to the International Classiﬁcation of Diseases (ICD),
until 1994 the ICD-8 and from 1994 the ICD-10. All patients are regis-
tered via a unique and permanent civil registration number. The
Danish Registry of Medicinal Product Statistics includes information
about all prescription medicines dispensed from pharmacies in
Denmark since 1995. All prescriptions are registered at an individual
level by using the civil registration number. The Registry classiﬁes
medicines according to the Anatomical Therapeutic Chemical
(ATC) system, an international classiﬁcation system of pharmaceuti-
cals. As all residents in Denmark are covered by a national health
security system and get the cost of drugs partly reimbursed, all
pharmacies are required by law to register all prescription
dispensed in this nationwide registry.
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Population
All patients aged 30 or older admitted with a diagnosis of ﬁrst AMI
(ICD-10: I21–I22) between 1995 and 2002 and alive 30 days after
discharge (180 days for statins) were identiﬁed from the National
Hospital Registry. The diagnosis of AMI in the National Hospital
Registry has been validated and has a sensitivity of 91% and predic-
tive value of 93%.3 The selection procedure and characteristics of
the patients have been detailed previously.4,5 We registered
whether patients had a prescription of beta-blockers (ATC code
C07) and ACE-inhibitors (ATC code C09—also including angiotensin
2 receptor blockers) dispensed 0–30 days from discharge after
ﬁrst AMI and statins (ATC code C10AA) dispensed 0–180 days from
discharge. The reason the interval for statins differed was that
the reimbursement policies for statins changed during the period.
In 1995, reimbursement required individual application, but after
1998, all AMI patients were reimbursed for the full cost of statins
without need for individual application.
All subsequent prescriptions were identiﬁed until the end of year
2002 or the date of death. Among patients who did not receive
treatment early after discharge, we identiﬁed those who started
treatment between 30 days and 1 year to estimate whether a
signiﬁcant proportion initiated treatment later. As the registries do
not include information of left ventricular function and that the
ICD-10 cod for heart failure has a relatively low sensitivity, the
dispensed prescription of loop diuretics (ATC code C03C) 90 days
before to 30 days after discharge was used as a proxy for the
diagnosis of heart failure. In the same way, dispensed prescription
of antidiabetics (ATC code A10) 90 days before to 30 days after
discharge was used as a proxy for the diagnosis of diabetes
mellitus.
Compliance
The Danish Registry of Medicinal Product Statistics includes
information about the dispensing date of the prescription, the
strength of the drug, and the total number of tablets dispensed
but not the prescribed dose of the drug. The dose of each prescrip-
tion was therefore calculated from the average dose given during
up to three consecutive prescriptions. Excess tablets were
allowed to be accumulated for up to three previous consecutive
prescriptions at any time. On the basis of these assumptions,
we calculated whether patients at any time had tablets available
or not. We deﬁned a patient as receiving treatment if tablets
were available.
To determine long-term compliance, we calculated whether
patients who did not receive treatment were in a break of 7, 30,
90, and 180 days or longer. We calculated the proportion of patients
who restarted therapy after a break of a particular length and found
that a substantial proportion of patients restarted treatment again
after a break shorter than 90 days. We therefore used a break of at
least 90 days as a proxy for poor compliance.
To validate the calculations, sensitivity analysis was performed
with the average daily dose calculated also from single prescrip-
tions, with the minimal dose equal to a previously calculated dose
for the same patient and allowing each patient to keep residual
tablets from one to ﬁve prescriptions. The manipulations resulted
in 75–85% agreement between the calculated doses and 2–4% with
changes in the number of patients stopping therapy.
Dosages
We calculated the average dosages of the most frequently used
medications within each group by multiplying the strength of the
formulation by the number of tablets per day. The average
dosage was calculated only for patients who had medication avail-
able for treatment. To estimate underdosing, we compared the
average dosage with the dosages used in major randomized clinical
trials.
Statistical analysis
For descriptive statistics, the results are given as mean values with
standard deviation or as median values with range. To analyse
differences in proportion in drug use and death rates between
1995 and 2002, we tested for linear trend in logistic regression
models. The rates of ﬁrst dispensing of treatment and break in
treatment were estimated by the Kaplan–Meier method. To
analyse the effect of available covariates (age, gender, year of
AMI, and concomitant medical treatment) on long-term compliance,
we used Cox multivariable proportional hazard models and censor-
ing for death. Model assumptions—the linearity of continuous
variables, the proportional hazard assumption, and lack of
interaction—were tested and found valid unless otherwise indi-
cated. Furthermore, we calculated the persistence of therapy,
deﬁned as number of patients having medicine available at any
time (having ﬁlled at least one prescription early after the AMI)
divided by the number of patients alive within particular treatment
group. Patients with missing information or lost to follow-up (emi-
grated), n ¼ 22 (0.04%), were censored at the time of disappear-
ance. All statistical calculations were performed using the SAS
statistical software package, version 8.2 for UNIX servers (SAS
Institute Inc., Cary, NC, USA).
Ethics
The Danish Data Protection Agency approved this study, and data
were made available to us such that individuals could not be
identiﬁed.
Results
During the 8-year study period, 71 515 patients had a ﬁrst
admission for AMI. The 30-day mortality was 22.7%,
ranging from 26.0% in 1995 to 17.4% in 2002 (P, 0.001).
A total of 55 315 patients were alive 30 days after discharge
and were included in the analysis of the use of beta-blockers
and ACE-inhibitors after AMI. The 48 412 patients who were
alive 180 days after discharge were included in the analysis
of statins. The baseline characteristics of the study popu-
lation are shown in Table 1.
Figure 1 illustrates the timing of the ﬁrst dispensing of
each of the three drugs during the ﬁrst year after AMI (cen-
sored for death). The probability of starting treatment was
low if treatment was not started early for beta-blockers
and ACE-inhibitors. Only 5621 (10.7%) patients started
beta-blocker treatment and 6694 (12.1%) ACE-inhibitors
between 31 days and 1 year after AMI. For statins, the
start of treatment was slower, but between day 181 and 1
year, only 2868 (5.9%) patients started therapy. From 1995
to 2002, the number of patients initiating beta-blocker
treatment later than 30 days after the infarction declined
from 11.5 to 9.3% (P, 0.001) and statins after 180 days
declined from 6.7 to 1.7% (P , 0.001), but the number of
patients receiving ACE-inhibitors after 30 days increased
from 10.5 to 12.0% (P, 0.001). Hospital-based physicians
issued the majority of the initial early prescriptions of
beta-blockers, ACE-inhibitors, and statins (Table 2). The
later prescriptions initiated were distributed almost
evenly between hospital-based physicians and general
practitioners.
Figure 2 illustrates the long-term compliance for patients
who ﬁlled a prescription for a beta-blocker or ACE-inhibitor
within 30 days of AMI or a statin within 6 months. Short
breaks in therapy were common, but many patients
restarted therapy later (Table 3). We used a break of at
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least 90 days to analyse factors of importance for poor
adherence with treatment.
The Cox multivariable proportional hazard analysis
(Table 4) revealed that although there were increasing
number of patients initiating treatment from 1995 to
2002, this did not affect compliance. On the contrary, com-
pliance improved with beta-blockers. Women had better
compliance with beta-blockers and statins than men, and
older patients had better compliance with beta-blockers
but worse compliance with ACE-inhibitors and statins.
Concomitant medical treatment did not worsen compliance,
except for patients taking loop diuretics had slightly poorer
compliance with beta-blockers.
Table 5 shows the average dosages of the most frequently
used beta-blockers, ACE-inhibitors, and statins. We analysed
whether dosages changed during the observation time by
comparing the average dosages used during the ﬁrst year
of treatment with the average dosages used between 3
and 5 years of treatment. This revealed that the average
dosages of beta-blockers and ACE-inhibitors changed only
between 2 and 7%. The average dosages of simvastatin and
pravastatin changed ,3%, but the dosages for atorvastatin
increased 21.5% from the ﬁrst year when compared with
3–5 years of therapy.
Discussion
This study has four main ﬁndings. (i) If prophylactic treat-
ment after a myocardial infarction is not initiated at the
time of discharge, the likelihood of ever receiving treatment
is small. (ii) If treatment is started early post-AMI, most
patients adhere to treatment for many years. (iii)
Initiation of treatment nearly always relies on the initiative
of the hospital physicians. (iv) The prescribed doses of
all three drugs were substantially lower than those
recommended and seldom adjusted during long-term
therapy.
Initiation of therapy
All three drugs were prescribed with increasing frequency
during the study period, the increase being most pro-
nounced for beta-blockers and statins. Beta-blockers and
ACE-inhibitors were primarily initiated during the ﬁrst 30
days after AMI, whereas statin therapy was more gradually
initiated during the ﬁrst 6 months (Figure 1). This was prob-
ably related to Denmark’s reimbursement policies, which
changed in 1998, and AMI patients no longer need to apply
individually for reimbursement of the cost of statin
therapy. Notably, the vast majority of early prescriptions
Table 1 Baseline characteristics of the study sample
Characteristics n %
Total patients
(mean age+ SD, years)
55 315
(67.6+ 12.8)
Women
(mean age+ SD, years)
20 361
(72.0+ 12.3)
36.8
Men
(mean age+ SD, years)
34 954
(65.1+ 12.5)
63.2
Year of AMI
1995 6 827 12.3
1996 6 485 11.7
1997 6 300 11.4
1998 6 514 11.8
1999 6 351 11.5
2000 7 156 12.9
2001 8 008 14.5
2002 7 674 13.9
Treatment
Beta-blockersa 32 259 58.3
ACE-inhibitorsb 16 068 29.1
Statinsc 16 433 33.5
Loop diuretics 20 323 36.7
Antidiabetic drugs 5 571 10.1
SD, standard deviation.
aRanging from 38.1% in 1995 to 67.9% in 2002 (P , 0.001).
bRanging from 24.5% in 1995 to 35.5% in 2002 (P , 0.001).
cRanging from 11.7% in 1995 to 63.0% in 2002 (P , 0.001).
Figure 1 Cumulative frequency of patients with ﬁrst AMI who ﬁlled a ﬁrst
prescription of beta-blocker, ACE-inhibitor, or statin within 1 year after
discharge (censored for death).
Table 2 First prescription claim of beta-blockers, ACE-inhibitors, and statins dispensed 0–30 days and 31–365 days from discharge, accord-
ing to the type of the physician issuing the prescription
Beta-blockers ACE-inhibitors Statins
0–30 days 31–365 days 0–30 days 31–365 days 0–180 days 181–365 days
General practitioner (%) 15.1 49.8 21.5 53.8 27.2 45.9
Specialist (private) (%) 0.5 0.9 0.6 1.1 0.7 1.0
Hospital physician (%) 84.4 49.3 77.9 45.1 72.1 53.1
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were written by hospital-based physicians, whereas general
practitioners initiated very few early prescriptions (Table 2).
The relatively few patients who started late had a more
even contribution by hospital-based physicians and general
practitioners, but the general practitioners still only
accounted for about half the initial prescriptions. Further,
the number of patients initiating treatment later than 30
days for beta-blockers and 180 days for statins from 1995
to 2002 declined substantially. This emphasizes the import-
ance of initiating treatment early, as the probability of
starting treatment later is low.
It is interesting that although treatment was mostly
initiated by hospital-based physicians, there still remains
substantial proportion of patients who do not start treat-
ment. Hospital-based physicians taking care of patients
with AMI are most often specialists in internal medicine or
cardiology, and thus should be updated in appropriate treat-
ment of AMI patients. Most likely, some discharging physi-
cians rely on the fact that the doctor taking care of the
AMI patient after discharge initiates appropriate therapy
not already started in the hospital, whereas doctors taking
care of the patient after discharge depend on the judge-
ment of the discharging physician. To prevent such misun-
derstanding, the discharging physician should initiate
treatment in the hospital and if not started at discharge
give clear message to the doctor taking care of the AMI
patient after discharge regarding further medical
treatment.
Long-term compliance with treatment
After 5 years of treatment, 58% of patients were still receiv-
ing beta-blockers, 74% ACE-inhibitors, and 82% statins
(Figure 2). The literature is sparse regarding studies on
long-term compliance with treatment post-AMI. Registries
that included selected departments have shown 6-month
compliance with ACE-inhibitors and beta-blockers exceed-
ing 80%.2,6 Studies from North America among patients
older than 65 years of age and patients participating in
speciﬁc insurance systems showed that 60–80% continued
treatment after 1 year.7 The most comprehensive long-
term studies available are studies of lipid-lowering
therapy. The long-term compliance in these studies was
50–85% after 1 year, 40–77% after 2–3 years, and 45–50%
after 5 years.8–14
The difﬁculty in comparing these numbers with those in
our study is that compliance has been deﬁned in many
different ways. Previous studies have not distinguished
between breaks and discontinuation. Most of our patients
restarted therapy after a break, especially after a brief
break (Table 3). Even after a break of at least 90 days,
almost half of the patients restarted therapy with beta-
blockers and ACE-inhibitors within 1 year and almost 70%
restarted statins.
To analyse the factors inﬂuencing long-term compliance,
we used the time to ﬁrst break of 90 days, or longer, in
multivariable proportional hazard analysis (Table 4). The
increase in early initiation of treatment during the study
period was not associated with decreased long-term
compliance—instead, compliance improved moderately but
statistically signiﬁcantly. Notably, multiple drug therapy
did not reduce compliance, and increased age and female
sex were also associated with improved compliance. These
results emphasize that an increased effort during the study
period to initiate more medicines in more patients was not
associated with worse compliance.
Dosages
Analysis of the dosages of the most frequently used drugs
within each class revealed substantial underdosing of
almost all medicines, with dosages generally 50% or less
than the dosages that randomized trials have proved to be
effective (Table 5).15–19 We also analysed whether dosages
changed from the ﬁrst prescription dispensed when
compared with later on but found that patients largely
stayed at their initial dosage. Deﬁning a target dose for
statins is more difﬁcult because this may be related to the
effect on serum cholesterol levels. Our data do not cover
patients’ cholesterol levels, and thus we cannot conclude
Figure 2 Persistence with therapy in patients who claimed at least one
prescription early after AMI. Each point represents number of patients with
available medication divided by the number of patients alive at that time.
Table 3 The proportion of AMI patients on beta-blocker, ACE-inhibitor, or statin therapy who experienced a break of at least 7, 30, 90, or
180 days within 5 years of treatment and the proportion who had re-initiated therapy within 1 year
Length of break Proportion experiencing a break Proportion re-initiating treatment within 1 year
Beta-blocker (%) ACE-inhibitor (%) Statin (%) Beta-blocker (%) ACE-inhibitor (%) Statin (%)
7 days 96.5 94.7 97.0 89.0 92.9 96.7
30 days 73.1 56.2 71.4 68.6 72.6 89.6
90 days 51.7 34.4 34.4 42.2 45.1 69.3
180 days 41.8 28.7 23.6 22.5 26.7 40.3
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about the dosages of statins. Although not as prominent as
for beta-blockers and ACE-inhibitors, the dosages of statins
were generally lower than those used in randomized
trials.20–22
Strengths and limitations of the study
The AMI diagnosis in the National Hospital Registry has been
validated and is sensitive as well as speciﬁc.3 The registry
includes all hospital admissions in Denmark from 1978 and
therefore not affected by selection bias by only including
selected hospitals, certain health insurance systems, or
age groups. A comprehensive accumulation of nationwide
admission data and linking to other registries is unique for
Denmark. Although the study is based on registries from a
single country, Denmark’s health insurance system, which
partly reimburses all patients for drug expenses, is typical
of many western countries.23
A break in therapy of at least 90 days was arbitrarily
selected to deﬁne long-term compliance, as one-third to
half of the population experienced break of at least 90
days. Analyses of the effects of shorter or longer breaks in
therapy did not change the results noticeably.
The diagnostic criteria for AMI changed in 1999, and
during the study period more sensitive diagnostic markers
have been introduced (i.e. troponins). Nevertheless, this
has not resulted in dramatic change in the prognosis of
AMI 24 and it is unlikely that this affects our study.
The National Hospital Registry does not include
information about basal clinical variables such as location
or size of infarction, smoking status, systolic function, and
co-morbidity. However, the indication for treatment with
beta-blocker or statin after AMI is independent of these
factors. Further, ACE-inhibitors are primarily indicated for
patients with reduced systolic function and diabetes. We
therefore used the concomitant use of loop diuretics and
antidiabetics as a proxy for, respectively, heart failure
Table 4 Cox multivariable proportional hazard analysis of covariates predicting ﬁrst break in therapy of more than 90 days (a proxy for low
compliance) with beta-blockers, ACE-inhibitors, and statins in patients with ﬁrst AMI, 1995–2002
Covariate Beta-blockers ACE-inhibitors Statins
RR 95% CI P RR 95% CI P RR 95% CI P
Calendar yeara
1995–96 1.00 1.00 1.00
1997–98 0.97 0.93–1.02 0.28 1.00 0.91–1.09 0.93 1.07 0.97–1.19 0.17
1999–2000 0.82 0.78–0.87 ,0.001 1.03 0.93–1.14 0.53 1.36 1.23–1.51 ,0.001
2001–02 0.80 0.75–0.86 ,0.001 0.92 0.81–1.05 0.20 1.04 0.92–1.17 0.54
Genderb
Women 1.00 1.00 1.00
Men 1.17 1.12–1.22 ,0.001 0.98 0.91–1.05 0.53 1.14 1.07–1.22 0.001
Agec
30–59 years 1.00 1.00 1.00
60–69 years 0.85 0.81–0.90 ,0.001 0.86 0.79–0.93 ,0.001 0.88 0.82–0.94 ,0.001
70–79 years 0.86 0.81–0.90 ,0.001 1.03 0.94–1.14 0.49 0.99 0.90–1.08 0.80
 80 years 0.88 0.82–0.95 ,0.001 1.16 1.05–1.28 0.003 1.40 1.16–1.68 ,0.001
Concomitant treatmentd
Beta-blocker — — — 0.95 0.88–1.03 0.21 0.90 0.83–0.96 0.002
ACE-inhibitor 0.92 0.88–0.96 ,0.001 — — — 0.87 0.81–0.94 ,0.001
Statins 0.93 0.89–0.97 ,0.001 0.92 0.85–0.98 0.04 — — —
Loop diuretics 1.07 1.02–1.12 0.006 0.91 0.85–0.98 0.009 0.94 0.87–1.02 0.15
Antidiabetics 0.97 0.90–1.04 0.35 0.84 0.75–0.93 0.001 1.06 0.95–1.19 0.28
RR, relative risk; CI, conﬁdence interval.
a1995–96 as reference.
bWomen as reference.
cAged 30–59 as reference.
dNon-users as reference.
Table 5 Average daily dosage of the most frequently used
beta-blockers, ACE-inhibitors, and statins after AMI
Medicationa Proportionb
(%)
Average daily
dosage [median
(IQR); mg]
Clinical trial
dosages
(mg)c
Beta-blockers
Metoprolol 76.8 75 (50–100) 200
Atenolol 7.6 50 (25–50) 100
Bisoprolol 6.5 5 (5–7.5) 10
Others 9.1
ACE-inhibitors
Trandolapril 26.3 2 (1.5–3) 4
Ramipril 25.9 5 (3.75–10) 10
Captopril 13.6 37.5 (25–62.5) 150
Enalapril 13.4 10 (7.5–20) 20
Others 20.8
Statins
Simvastatin 63.8 20 (10–20) 40
Atorvastatin 15.9 10 (10–20) 80
Pravastatin 15.2 40 (20–40) 40
Others 5.1
IQR, interquartile range.
aThe most frequently used medications within each class.
bProportion of all medications used within each class.
cDosages used in randomized clinical trials with clinical endpoint
reduction.
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and diabetes, to deﬁne subgroups of patients where there
was deﬁnite indication for treatment. The registries do not
include information about contraindications to treatment,
adverse reactions, or allergies that might have caused the
treatment not to start or to be terminated early after
start. Also, we do not know how many patients started
treatment in hospital and did not continue treatment after
discharge. Furthermore, factors such as race/ethnicity,
history of depression or other psychiatric illness, and the
specialty of the physician taking care of patient could also
inﬂuence long-term compliance.
Clinical implications
This study demonstrates that long-term compliance can be
expected if treatment with beta-blockers, ACE-inhibitors,
and statins is started early after AMI, although dosages are
seldom uptitrated during long-term therapy. In contrast, if
therapy is not started in the early phase after AMI, the
patient is unlikely to ever receive appropriate medical
treatment. Most general practitioners and other physicians
treating survivors of AMI seem to rely on the initiative and
judgement of the hospital department from which the
patient is discharged. This underscores the importance of
hospital departments initiating appropriate long-term
therapy in survivors of AMI. A more focused effort from
hospitals treating AMI patients in starting these patients
on relevant medicines and titrating them to an effective
dose will result in long-term beneﬁts.
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